日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

贝祖替凡抑制肾细胞癌中缺氧诱导因子-2α:一项I期临床试验和生物标志物分析

Choueiri, Toni K; Bauer, Todd M; Papadopoulos, Kyriakos P; Plimack, Elizabeth R; Merchan, Jaime R; McDermott, David F; Michaelson, M Dror; Appleman, Leonard J; Thamake, Sanjay; Perini, Rodolfo F; Zojwalla, Naseem J; Jonasch, Eric

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

PT2385(一种首创的缺氧诱导因子-2α拮抗剂)在既往接受过治疗的晚期透明细胞肾细胞癌患者中的I期剂量递增试验

Courtney, Kevin D; Infante, Jeffrey R; Lam, Elaine T; Figlin, Robert A; Rini, Brian I; Brugarolas, James; Zojwalla, Naseem J; Lowe, Ann M; Wang, Keshi; Wallace, Eli M; Josey, John A; Choueiri, Toni K

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

一项开放标签、随机、III期ASPIRE试验评估了卡非佐米、来那度胺和地塞米松与来那度胺和地塞米松治疗复发性多发性骨髓瘤患者的疗效,结果显示,这些患者的健康相关生活质量与卡非佐米、来那度胺和地塞米松联合治疗效果相当。

Stewart, A Keith; Dimopoulos, Meletios A; Masszi, Tamás; Špička, Ivan; Oriol, Albert; Hájek, Roman; Rosiñol, Laura; Siegel, David S; Niesvizky, Ruben; Jakubowiak, Andrzej J; San-Miguel, Jesus F; Ludwig, Heinz; Buchanan, Jacqui; Cocks, Kim; Yang, Xinqun; Xing, Biao; Zojwalla, Naseem; Tonda, Margaret; Moreau, Philippe; Palumbo, Antonio

Cancer screening practices of Asian American physicians in New York City

纽约市亚裔美国医生的癌症筛查实践

Bodle, Ethan E; Islam, Nadia; Kwon, Simona C; Zojwalla, Naseem; Ahsan, Habibul; Senie, Ruby T